Dariohealth CORP (DRIO) Institutional Ownership & 13F Filings (Q2 2026)

AI summary pending

DarioHealth Corp. says its President and Chief Commercial Officer, Steven Nelson, will step down from his officer roles on September 1, 2026, with his employment formally ending September 30, 2026, after his medical leave was extended indefinitely back in July. Under the separation agreement, he receives his earned wages and unused vacation time, health coverage through the end of September, and up to three months of COBRA reimbursement at $2,600 per month, while any unvested equity awards expire when his employment ends. Starting October 1, he moves into a consulting role through December 31, 2027—monthly advisory calls, industry insights, and strategic introductions—in exchange for 30,000 restricted shares (still pending Compensation Committee approval) that vest after one year, with half vesting immediately if the company terminates the consulting deal.

DarioHealth Corp. has entered into a securities purchase agreement with institutional investors to sell about 2.44 million shares and 1.02 million pre-funded warrants in a registered direct offering priced at $6.80 per share and $6.7999 per warrant. The deal is expected to raise roughly $23.5 million in gross proceeds before expenses. A board member, Dennis Matheis, also agreed to buy 14,430 shares at $6.93 each. The offering is set to close on July 23, 2026.

DarioHealth Corp. disclosed in an 8-K filed on July 10, 2026, that the temporary medical leave of its President and Chief Commercial Officer, Steven Nelson, has been extended indefinitely. His responsibilities are now being covered by other members of the senior management team.